<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639558</url>
  </required_header>
  <id_info>
    <org_study_id>DPAP - 2018 - 0138 - 1</org_study_id>
    <nct_id>NCT03639558</nct_id>
  </id_info>
  <brief_title>TREC-Lebanon: A Trial for Rapid Tranquilisation for Agitated Patients in the Emergency Setting</brief_title>
  <acronym>TREC</acronym>
  <official_title>TREC-Lebanon Trial: A Randomised Controlled Trial for Rapid Tranquilisation for Agitated Patients in the Emergency Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Dib</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital Psychiatrique De La Croix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hopital Psychiatrique De La Croix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised controlled trial comparing haloperidol + promethazine versus haloperidol
      + promethazine + chlorpromazine for agitated patients in the emergency department.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Actual">July 7, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing change of patient's aggressive behavior to calm and tranquil.</measure>
    <time_frame>20, 40, 60 and 120 minutes post intervention treatment</time_frame>
    <description>Patient no longer exhibiting aggressive behavior both verbal and physical post intervention treatment. A primary measure of outcome form will contain a Calm or Tranquil column followed by four rows: 20 mins, 40 mins, 60 mins and 120 mins post intervention medication. The boxes would be ticked depending if the patient meets the primary measure of outcome within the time frame provided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time taken for patient to fall Asleep</measure>
    <time_frame>20, 40, 60 and 120 minutes post intervention treatment</time_frame>
    <description>Patient has fallen asleep and is no longer aggressive post intervention treatment and will be noted on the outcomes form which includes a checklist of different time intervals: 20, 40, 60 and 120 minutes post intervention treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time patient was placed in Straitjacket/Restraint post intervention treatment</measure>
    <time_frame>20, 40, 60 and 120 minutes post intervention treatment</time_frame>
    <description>If patient was placed in a straitjacket post intervention due to aggression - this would be noted on the outcomes form which includes a checklist at certain time intervals 20,40,60 and 120 minutes post intervention treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time noted where Important Adverse Effects occurred post intervention</measure>
    <time_frame>20, 40, 60 and 120 minutes post intervention treatment</time_frame>
    <description>If patient exhibits any adverse effects post intervention treatment, it would be noted on the outcomes form either at 20,40, 60 or 120 minutes post intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time patient left the ward against medical advice during the time period after the intervention was administered.</measure>
    <time_frame>20, 40, 60 and 120 minutes post intervention treatment</time_frame>
    <description>If patient had to leave ward against medical advice during intervention phase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Psychiatric Emergency</condition>
  <condition>Aggression</condition>
  <condition>Agitation</condition>
  <arm_group>
    <arm_group_label>Haloperidol + Promethazine + Chlorpromazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Haloperidol + Promethazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol + Promethazine + Chlorpromazine</intervention_name>
    <description>This is the usual treatment given by this hospital during an aggressive psychiatric episode.</description>
    <arm_group_label>Haloperidol + Promethazine + Chlorpromazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol + Promethazine</intervention_name>
    <description>This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.</description>
    <arm_group_label>Haloperidol + Promethazine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient will be eligible if (1) requiring emergency acute intramuscular sedation
             because of disturbed and dangerous behaviour and (2) if the clinician is uncertain of
             the benefits between haloperidol plus promethazine vs haloperidol plus promethazine
             plus chlorpromazine.

          -  Gender - both male and female

          -  Age (18-64)

          -  Clinician is unaware on the effects of either treatment interventions

        Exclusion Criteria:

          -  If the clinician KNOWS one treatment has benefit over another for a particular person

          -  If the clinician is aware of a contra-indication of one of the treatments

          -  If there is an Advanced Directive expressing a wish for one or other, or another
             treatment in the emergency setting.

          -  If the clinician does not want to undertake for both personal and professional
             reasons.

          -  If the participant is known to be allergic to one or more of the interventions

          -  Already randomized

          -  Already sedated

          -  Accompanying person (Friend/Family/Police Officer) refuses patient trial entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HÃ´pital Psychiatrique De La Croix</name>
      <address>
        <city>Beirut</city>
        <state>Jal L Dib</state>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Hospital of the Cross</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hopital Psychiatrique De La Croix</investigator_affiliation>
    <investigator_full_name>Joseph Dib</investigator_full_name>
    <investigator_title>Director of Trial Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Chlorpromazine</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

